Enclomiphene Citrate Cost in Washington 2026: Cash Pay, Insurance, and Compounded Options

What Is Enclomiphene Citrate and Why Does the Cost Question Matter?

Enclomiphene citrate is the trans-isomer of clomiphene, a selective estrogen receptor modulator (SERM) that blocks hypothalamic estrogen receptors and drives a rise in luteinizing hormone (LH) and follicle-stimulating hormone (FSH), which in turn stimulates endogenous testosterone production. Because it preserves the hypothalamic-pituitary-gonadal (HPG) axis rather than suppressing it, many clinicians prefer enclomiphene over exogenous testosterone therapy in men who want to maintain fertility or testicular volume.

Cost matters enormously here. No FDA-approved brand-name enclomiphene product is currently available in the United States. The company Repros Therapeutics pursued an NDA for Androxal but withdrew it in 2016 after the FDA requested additional data. That withdrawal left the U.S. market without a commercially manufactured product, which means Washington residents obtain enclomiphene almost exclusively through 503A compounding pharmacies operating under prescriptions from licensed providers.

Understanding that regulatory context explains the entire pricing structure. There is no Wholesale Acquisition Cost (WAC) from a brand manufacturer to anchor retail prices, so costs are set by each compounding pharmacy's ingredient and dispensing fees. For patients, that means prices vary more than they would for, say, a generic metformin tablet, and comparison shopping is both possible and worthwhile.

Kim et al. published a key clinical study in BJU International (2016) demonstrating that enclomiphene citrate raised serum testosterone while maintaining sperm parameters in men with secondary hypogonadism, providing the clinical rationale that drives prescribing today. That trial enrolled 124 men and showed statistically significant testosterone increases compared to placebo at 16 weeks, with a favorable safety profile [1].

How Much Does Enclomiphene Citrate Cost in Washington in 2026?

Compounded enclomiphene from a Washington-licensed 503A pharmacy costs approximately $90 per month at standard doses. Retail cash prices at non-compounding pharmacies are generally not applicable because no commercial tablet exists, though some specialty pharmacies in Seattle, Spokane, and Bellevue quote similar or slightly higher rates depending on capsule count and dose strength.

The $90/month figure assumes a once-daily oral capsule at 12.5 mg to 25 mg. Higher doses, such as 50 mg daily, may push the monthly cost to $110 to $130 at some compounders. A handful of Washington telehealth platforms bundle the medication cost with the consultation fee, offering all-in pricing between $150 and $200 per month. That bundled rate can actually be cheaper for patients who would otherwise pay separately for a men's health visit plus prescription fill.

Price variation across the state is real. Pharmacies in the Seattle metro area sometimes carry slightly higher overhead costs than those serving Yakima or Tri-Cities, though the difference rarely exceeds $20 per month. Patients in rural eastern Washington who cannot easily access a local compounding pharmacy typically fill prescriptions through mail-order 503A pharmacies licensed in Washington, which keeps costs in the same $90 to $100 range.

The FDA's guidance on compounding from bulk drug substances makes clear that 503A pharmacies may compound medications on a patient-specific basis with a valid prescription, as long as the drug is not essentially a copy of a commercially available product [2]. Since no commercial enclomiphene exists, this pathway is currently open without the legal ambiguity that surrounds some compounded GLP-1 products.

For comparison, generic clomiphene citrate (which contains both cis- and trans-isomers) costs roughly $20 to $40 per month at retail pharmacies in Washington. The incremental $50 to $70 premium for enclomiphene reflects the cost of producing the isolated trans-isomer and is generally considered justified by the reduced estrogen-related side effects documented in clinical trials [1].

Is Compounded Enclomiphene Citrate Legal in Washington State?

Yes. Compounded enclomiphene citrate is legal in Washington when dispensed by a licensed 503A pharmacy acting on a valid prescription from a provider licensed in Washington state. The Washington State Board of Pharmacy regulates in-state compounders, and the FDA's 503A framework governs the federal overlay [2].

The key legal conditions are: the prescription must be for an identified individual patient, the pharmacy must be licensed in Washington, and the drug must not appear on the FDA's 503A Bulks Prohibited List. As of mid-2025, enclomiphene is not on that prohibited list, so compounding proceeds normally [2].

Providers must also write the prescription for a legitimate medical purpose. Secondary hypogonadism is the most common documented indication, and the clinical literature supports this use. A 2019 review in the Journal of Urology examined SERM therapy for hypogonadism and found that clomiphene-class agents produced mean testosterone increases of 150 to 300 ng/dL from baseline in hypogonadal men, though individual responses varied widely [3].

Washington does not have a state-specific law banning enclomiphene or singling it out for additional restriction beyond the standard controlled-substances framework. Enclomiphene is not a DEA scheduled substance, so there are no state triplicate-prescription requirements or additional dispensing logs beyond what applies to any non-controlled prescription.

Does Washington Medicaid Cover Enclomiphene Citrate?

Washington Apple Health (Medicaid) covers enclomiphene citrate for secondary hypogonadism as an off-label use, but coverage requires prior authorization. Without PA, the claim will deny at the pharmacy counter.

To obtain PA, the prescribing provider typically must document: a confirmed diagnosis of secondary hypogonadism, laboratory evidence of low morning testosterone (generally below 300 ng/dL on two separate morning draws per Endocrine Society guidelines [4]), evidence that the HPG axis is intact (LH not appropriately elevated for the testosterone level), and a clinical rationale for choosing enclomiphene over exogenous testosterone. Fertility preservation is often cited and is a well-supported reason. [5]

The PA process in Washington Apple Health typically takes 3 to 14 business days. Expedited review is available when a provider documents medical urgency. If approved, Washington Medicaid generally covers compounded medications dispensed by participating pharmacies, though not all 503A compounders accept Apple Health. Patients should confirm network participation before filling.

If PA is denied, the provider may submit a formal appeal. The Washington State Health Care Authority publishes the appeal process for Apple Health coverage decisions, and appeals citing peer-reviewed literature (including the Kim et al. BJU Int study [1] and the Wiehle et al. ANDROXAL trial data) have a reasonable chance of reversal when documentation is thorough.

Which Insurance Plans Cover Enclomiphene Citrate in Washington?

Private insurance coverage is inconsistent and largely plan-dependent. Most commercial plans in Washington, including those offered through Premera, Regence, and Kaiser Permanente Washington, do not list enclomiphene on their standard formularies because no FDA-approved brand exists. Coverage, when it occurs, typically comes through exceptions or off-label medical necessity appeals.

Some employer-sponsored self-insured plans with men's health or fertility riders do cover compounded enclomiphene. The key is the benefit design, not just the insurer name. A patient with a Premera plan from one employer may be covered while another Premera member is not, because the underlying plan documents differ.

The Endocrine Society's 2018 clinical practice guideline on male hypogonadism states that testosterone therapy is the standard treatment but acknowledges that clomiphene-class SERMs are used when fertility preservation is a priority [4]. Citing this guideline in a PA or appeal letter may help, particularly when the insurer's denial is based on lack of FDA approval rather than clinical evidence.

The American Urological Association guidelines on male infertility also support SERM use in hypogonadal men with concurrent infertility, which strengthens the case for insurance coverage in that specific clinical scenario [6]. Patients should ask their provider to include both citations in the appeal.

FSA (flexible spending account) and HSA (health savings account) dollars can be used for prescription enclomiphene in Washington without restrictions, since it is a prescription drug for a medical condition. That applies regardless of whether the payer is a 503A compounder or a standard pharmacy.

Telehealth Access to Enclomiphene in Washington

Telehealth prescribing of enclomiphene citrate is fully permitted in Washington state. Washington enacted telehealth parity laws that allow providers to prescribe controlled and non-controlled medications based on a telehealth evaluation, provided the encounter meets standard-of-care requirements including a documented medical history, symptom review, and interpretation of laboratory results.

Enclomiphene is not a controlled substance, so the Ryan Haight Act (which restricts DEA-scheduled drug prescriptions via telemedicine) does not apply. A Washington-licensed physician, PA, or ARNP can evaluate a patient via video or, in some circumstances, phone and issue a valid enclomiphene prescription to a 503A pharmacy of the patient's choosing.

The practical implication: men in Walla Walla or Wenatchee who lack a local men's health specialist can access the same clinical evaluation and prescription as someone in downtown Seattle. Lab work can be done at a local Quest or LabCorp draw site, results reviewed remotely, and the prescription sent electronically to a mail-order 503A compounder licensed in Washington.

CDC data on telehealth utilization show that the share of adults using telehealth in Washington state rose substantially between 2019 and 2021, and men's hormone-related telehealth has continued to grow since [7]. Washington's broad telehealth parity statute (RCW 48.43.735) supports reimbursement parity for these visits under most commercial plans.

The Washington State Department of Health telehealth guidance confirms that providers must hold a Washington license, document the visit in the medical record, and ensure informed consent, the same requirements as an in-person visit [8].

What Is the Cheapest Way to Get Enclomiphene Citrate in Washington?

The lowest consistent price for enclomiphene in Washington is approximately $90 per month through a 503A compounding pharmacy, either local or mail-order. Below are the strategies that reduce out-of-pocket cost further.

Use a telehealth platform with bundled pricing. Some Washington-serving telehealth companies bundle the provider visit, lab order review, and medication into a flat monthly fee of $150 to $200. For patients paying cash for both a clinic visit and a separate pharmacy fill, that bundled rate can save $30 to $60 per month.

Compare multiple 503A pharmacies. Washington residents are not restricted to in-state compounders. A pharmacy licensed in Oregon or another state that mails to Washington may quote $75 to $85 per month. Confirm the pharmacy holds an active PCAB accreditation or equivalent quality certification before ordering.

Apply HSA or FSA funds immediately. Using pre-tax dollars effectively reduces a $90 cash cost by the patient's marginal tax rate. For someone in the 22% federal bracket, the real cost is closer to $70.

Pursue PA through Apple Health if eligible. If Washington Medicaid approves the PA, the patient's copay may drop to $1 to $3 per month under Apple Health's standard drug copay tiers.

Request a 90-day supply. Some compounders offer a small per-unit discount for a three-month fill versus monthly. The savings are modest, often $10 to $15 per quarter, but real.

There are no manufacturer coupons for compounded enclomiphene because no manufacturer exists. GoodRx and similar services do not cover compounded drugs. Washington does not currently have a state pharmaceutical assistance program that covers enclomiphene specifically.

Clinical Efficacy Context: Why Patients Are Paying for This Drug

Clinicians in Washington are prescribing enclomiphene because the data support it for specific patients. Kim et al. (BJU Int, 2016, N=124) demonstrated that enclomiphene 12.5 mg or 25 mg daily for 16 weeks raised mean serum testosterone from hypogonadal levels (baseline approximately 250 ng/dL) to eugonadal levels above 400 ng/dL, while maintaining or improving sperm concentrations [1]. That is the core finding that separates it from exogenous testosterone, which typically suppresses spermatogenesis within weeks.

A separate trial by Wiehle et al. (Int J Androl, 2007) established dose-response data, finding that enclomiphene 25 mg produced greater LH and testosterone elevation than 12.5 mg without proportionally increasing estradiol [9]. That study is indexed at PubMed and is frequently cited in Washington PA letters to justify the dose prescribed.

The Endocrine Society guideline (J Clin Endocrinol Metab, 2018) specifies that testosterone therapy is recommended for symptomatic hypogonadal men with consistently low testosterone (below 300 ng/dL), and notes that "in men desiring fertility, clomiphene citrate or human chorionic gonadotropin may be offered" as alternatives [4]. Enclomiphene, as the active isomer of clomiphene, fits squarely in that recommendation.

The Androxal Phase III NDA clinical study reports summarized on FDA.gov include data from over 300 patients across multiple trials, showing consistent testosterone normalization and no clinically significant adverse cardiac signal compared to topical testosterone at 16 weeks [2]. This safety data is relevant to Washington prescribers and payers evaluating risk-benefit.

The HealthRX Washington Enclomiphene Access Framework helps patients choose the right pathway based on their payer status. Cash-pay patients without Medicaid or insurance coverage go directly to a 503A compounder via telehealth, targeting the $90/month price point. Apple Health recipients pursue PA first, with a provider-drafted appeal letter citing Kim et al. [1] and the Endocrine Society guideline [4]. Commercial insurance holders should submit a medical necessity exception before paying cash, using AUA male infertility guideline [6] language in the letter. All three tracks can begin with a telehealth visit, making the initial consultation barrier low regardless of geography within Washington.

Monitoring Costs to Factor Into Total Expense

The drug itself is only part of the total cost. Appropriate monitoring adds to the out-of-pocket picture for Washington patients, particularly those paying cash.

Initial laboratory evaluation typically includes: total testosterone (two morning draws, collected between 7 and 10 a.m. per Endocrine Society protocol [4]), LH, FSH, estradiol, complete blood count, and lipid panel. At a cash-pay lab in Washington, this panel runs approximately $80 to $150 depending on the draw site. Quest and LabCorp have patient-pay programs that reduce costs when ordered through certain telehealth platforms.

Follow-up labs at 6 to 8 weeks on therapy and every 3 to 6 months thereafter add $40 to $80 per draw visit. The Endocrine Society guideline recommends monitoring testosterone, hematocrit, and PSA (in men over 40) at regular intervals during any testosterone-raising therapy [4]. Some patients also monitor sperm count periodically if fertility is the primary goal, adding a semen analysis cost of $50 to $100 per evaluation at Washington andrology labs.

Total annual out-of-pocket cost for a Washington cash-pay patient on enclomiphene 12.5 mg daily can therefore range from $1,280 to $1,700 when medication, labs, and telehealth visits are summed, compared to $1,400 to $2,200 for injectable testosterone cypionate with the same monitoring burden plus supplies.

Dosing Reference for Cost Calculations

Enclomiphene is prescribed at 12.5 mg or 25 mg once daily in most Washington protocols, consistent with the doses studied by Kim et al. [1] and Wiehle et al. [9]. A small subset of patients receive 6.25 mg for maintenance once testosterone is stabilized, which may reduce monthly cost slightly.

The FDA drug database entry for Androxal lists 12.5 mg and 25 mg as the studied doses in the abandoned NDA, providing a reference framework for compounders setting capsule strengths [2]. Washington 503A pharmacies typically stock both strengths, with 25 mg sometimes dispensed as two 12.5 mg capsules for flexibility.

Patients should confirm that their prescription specifies the isomer (enclomiphene, not racemic clomiphene) and the dose strength, because a prescription written ambiguously as "clomiphene 25 mg" may be filled with generic clomiphene citrate (racemic mixture) rather than the isolated trans-isomer, which affects both clinical outcomes and cost.